SCHEMBL312653

SCHEMBL312653

O=c1cc(-c2ccc(O)cn2)oc2cccc(O)c12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 12/20 0.63
▸ CYP3A4 P08684 4/20 0.63
▸ MAPT P10636 4/20 0.63
▸ MEN1 O00255 4/20 0.63
▸ KMT2A Q03164 4/20 0.63
▸ MAPK1 P28482 2/20 0.63
▸ RAF1 P04049 1/20 0.63
▸ HPGD P15428 1/20 0.63
▸ ALOX15 P16050 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ CYP1A1 P04798 1/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ PKM P14618 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ CYP1B1 Q16678 1/20 0.57
▸ FTO Q9C0B1 1/20 0.57
▸ KDM4E B2RXH2 1/20 0.55
▸ ALOX5 P09917 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ ALOX12 P18054 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311843 0.84 CYP3A4 (0.59) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL312714 0.82 TNKS (0.62) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL311288 0.80 LOXL2 (0.47) CYP3A4MAPTMEN1KMT2AMAPK1
SCHEMBL157490 0.78 AR (1.00) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL24046768 0.77 CSNK2A2 (0.51) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL311280 0.77 HPGD (0.61) CYP3A4MAPTMEN1KMT2AMAPK1
SCHEMBL311667 0.77 CYP3A4 (0.61) CYP3A4MAPTMEN1KMT2AMAPK1
SCHEMBL311760 0.75 AR (0.68) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL6094870 0.74 CYP3A4 (0.85) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL24046890 0.74 ABCB1 (0.60) CYP3A4MAPTMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 — — US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 — — EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 — — US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 — — EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 — — US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 AR 2406/4885CYP3A4 1730/4885MAPT 2914/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 AR 2406/4885CYP3A4 1730/4885MAPT 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback